CTRI/2023/07/055757尚未招募Unknown
A Prospective, Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Impact of GLUBLOC™ on postprandial blood glucose and insulin levels in healthy individuals post high carbohydrate meal intake. - Not Applicable
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Aged between 18 to 60 years,
- •BMI between 20 and 29.9 kg per m2
- •Fasting blood glucose less than 6.1 mmol per l (or) less than 99 mg per dl
排除标准
- •History of hypersensitivity to any of the investigational product excipients or Any known food allergies
- •Pre existing medical condition or taking medication known to affect glucose regulation and or influence digestion and absorption of nutrient of diabetes mellitus type I and II or they used antihyperglycemic drugs or insulin to treat diabetes or related conditions
- •Used steroids, protease inhibitors or antipsychotic medicines as these drugs are known to impact glucose metabolism and body fat distribution
- •Subjects with the history of uncontrolled hypertension and or hyperthyroidism
- •History of alcoholism
- •Subjects with psychiatric or neurological disability or mental health disorder
- •Subjects with serious health conditions such as cardiac disease, renal dysfunction, and cancers.
- •Female subjects who are pregnant or had planned for pregnancy in the following months or were breast feeding
- •Subjects who refuse to sign informed consent
- •Those who have participated in another clinical trial within 1 month of visit 1 or plan to participate during the clinical trial period
- •According to the investigator’s opinion participants who are deemed unable to comply with the test requirements or otherwise deemed unsuitable
研究者
相似试验
进行中（未招募）
1 期
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults. - LIPOSSuspected or Confirmed Gram-negative Severe Sepsis in AdultsEUCTR2004-000406-51-DKSepsicure LLC
进行中（未招募）
不适用
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults. - LIPOSEUCTR2004-000406-51-CZGlaxoSmithKline,s.r.o.1,890
进行中（未招募）
不适用
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults. - LIPOSSuspected or Confirmed Gram-negative Severe Sepsis in AdultsEUCTR2004-000406-51-HU1,890
进行中（未招募）
1 期
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults. - LIPOSEUCTR2004-000406-51-ESGlaxoSmithkline, S.A.
进行中（未招募）
不适用
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults. - LIPOSEUCTR2004-000406-51-ATSepsicure LLC1,890